Search hospitals > Quebec > SHERBROOKE
DIEX Recherche Sherbrooke, Inc
Claim this profileSHERBROOKE, Quebec J1L 0H8
Conducts research for Alzheimer's Disease
Conducts research for Psoriasis
Conducts research for Atopic Dermatitis
Conducts research for Type 2 Diabetes
Conducts research for Chronic Cough
87 reported clinical trials
3 medical researchers
Summary
DIEX Recherche Sherbrooke, Inc is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Alzheimer's Disease, Psoriasis, Atopic Dermatitis, Type 2 Diabetes, Chronic Cough and other specialties. DIEX Recherche Sherbrooke, Inc is involved with conducting 87 clinical trials across 123 conditions. There are 3 research doctors associated with this hospital, such as Marcel Germain, Marylene Dussault, and Daniel Minier.Top PIs
Marcel GermainDiex Recherche Sherbrooke Inc.5 years of reported clinical research
Studies Dementia
Studies Cognitive Impairment
2 reported clinical trials
2 drugs studied
Marylene DussaultDiex Recherche Sherbrooke Inc.4 years of reported clinical research
Studies Cognitive Impairment
Studies Tauopathies
1 reported clinical trial
2 drugs studied
Daniel MinierDIEX Recherche Sherbrooke Inc.3 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Discoid Lupus
1 reported clinical trial
3 drugs studied
Clinical Trials running at DIEX Recherche Sherbrooke, Inc
Crohn's Disease
Type 2 Diabetes
Bullous Pemphigoid
Antiphospholipid Syndrome
Hidradenitis Suppurativa
Systemic Lupus Erythematosus
Cutaneous Lupus Erythematosus
Obesity
Inflammatory Bowel Disease
Ulcerative Colitis
Tulisokibart
for Crohn's Disease
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
Recruiting1 award Phase 31 criteria
Targeted Therapies
for Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. The medicines assessed in this study are risankizumab, ABBV-382 and lutikizumab. When participants join the study, they will be randomized into available study treatment groups. Adult participants with CD will be enrolled. Around 500 participants will be enrolled in the study at approximately 300 sites worldwide. Risankizumab and ABBV-382 are given as an injection under the skin or as an infusion into the vein. Lutikizumab is given as an injection under the skin. Each group includes a 12-week induction period, a 12-week maintenance period, and an optional long-term extension period where medication will be given after the maintenance period. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, endoscopies, checking for side effects and completing questionnaires and a daily diary.
Recruiting1 award Phase 21 criteria
MORF-057
for Crohn's Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Recruiting0 awards Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at DIEX Recherche Sherbrooke, Inc?
DIEX Recherche Sherbrooke, Inc is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Alzheimer's Disease, Psoriasis, Atopic Dermatitis, Type 2 Diabetes, Chronic Cough and other specialties. DIEX Recherche Sherbrooke, Inc is involved with conducting 87 clinical trials across 123 conditions. There are 3 research doctors associated with this hospital, such as Marcel Germain, Marylene Dussault, and Daniel Minier.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.